Abstract:OBJECTIVE To investigate the expression of the matrix metalloproteinases (MMP)-2, -3, and 9, tissue inhibitor of matrix metalloproteinase-1 (TIMP-1), fibronectin (FN), and tenascin-C (TN-C) in the myocardium, and their relationship with the myocardial remodeling and heart function in the patients with congestive heart failure (CHF). METHODS A few tissues of papillary muscles of left ventricle were taken from 39 patients with mitral insufficiency during mitral valve replacement, and from 8 organ donors who had died of accidents to undergo pathological examination and to detect the protein expression of MMP-2, -3, and 9, and TIMP-1 by immunoprecipitation and the expression of FN and TN-C by immunofluorescence test. Peripheral blood samples were collected from these 39 patients and 30 normal controls to examine the plasma MMPs and TIMP-1 by ELISA. RESULTS Typical myocardial remodeling was seen in the myocardial tissues of the CHF patients. The plasma levels of MMP-2, -3, and -9 of the CHF patients in the cardiac function classes II - IV were all significantly higher than those of the normal controls (P < 0.05 or P < 0.01) with a tendency to increase with the deterioration of heart function, The plasma level of TIMP-1 of the CHF patients in the cardiac function classes II - IV were all significantly higher than that of the normal controls (P < 0.05 or P < 0.01) with a tendency to decrease with the deterioration of heart function. The protein expression levels of MMP-2, -3, and -9 in the myocardium of the CHF patients in the cardiac function classes III - IV were all significantly higher than those of the normal controls (P < 0.05 or P < 0.01) with a tendency to increase with the deterioration of heart function. The protein expression levels of TIMP-1 in the myocardium of the CHF patients in the cardiac function classes III - IV were all significantly lower than that of the normal controls (P < 0.05 or P < 0.01) with a tendency to decrease with the deterioration of heart function. The protein expression levels of FN in the myocardium of the CHF patients in the cardiac function classes II - IV were all significantly lower than that of the normal controls (all P < 0.05) with a tendency to decrease with the deterioration of heart function. The protein expression levels of TN-C in the myocardium of the CHF patients in the cardiac function classes II - IV were all significantly higher than that of the normal controls (all P < 0.01) with a tendency to increase with the deterioration of heart function. CONCLUSION The increasing expression of MMP-2, -3, and -9 and the decreasing expression of TIMP-1 contribute to the myocardial remodeling, thus changing the extracellular matrix in the myocardium tissue and leading to the development and progression of CHF.

[Effects of matrix metalloproteinase-9 and tissue inhibitor-1 of metalloproteinase expression on atrial structural remodeling during chronic atrial fibrillation].

Effect of Matrix Metalloproteinase-9 and Tissue Inhibitor-1 of Metalloproteinase Expression on Atrial Structural Remodeling During Chronic Atrial Fibrillation

Differential gene expression during atrial structural remodeling in human left and right atrial appendages in atrial fibrillation.

Expression of Matrix Metalloproteinase and Cytokines During Atrial Fibrillation Investigation

Possible involvement of fibrocytes in atrial fibrosis in patients with chronic atrial fibrillation.

[Expression of Connexin in Atrium of Patients with Atrial Fibrillation and Its Signal Transduction Pathway].

The collagen metabolism and the expression of matrix metalloproteinase during atrial fibrillation

Atrial Extracellular Matrix Remodeling and the Maintenance of Atrial Fibrillation

Matrix Metalloproteinase-9/Tissue Inhibitors of Metalloproteinase-1 Expression and Atrial Structural Remodeling in A Dog Model of Atrial Fibrillation: Inhibition with Angiotensin-Converting Enzyme

Expression of matrix metalloproteinase in pulmonary vein myocardial sleeves in a canine model of persistent atrial fibrillation by rapid pulmonary vein pacing

E0356 the Research on Calcium Homeostasis Expression and Gene Transcription of Atrial Myocytes in Patients with Atrial Fibrillation

Change of gene expression of hepatocyte growth factor, connective tissue growth factor and trails forming growth factor-beta 1 in human atrium during atrial fibrillation

Role of the MAPKs/TGF-β1/TRAF6 Signaling Pathway in Atrial Fibrosis of Patients with Chronic Atrial Fibrillation and Rheumatic Mitral Valve Disease.

[Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure].

Changes In Matrix Metalloproteinase-9 Levels During Progression Of Atrial Fibrillation

MicroRNA‐146b‐5p promotes atrial fibrosis in atrial fibrillation by repressing TIMP4

From changes in local RAAS to structural remodeling of the left atrium: A beautiful cycle in atrial fibrillation.

Different Structural Remodelling in Atrial Fibrillation with Different Types of Mitral Valvular Diseases.

Does the expression of transforming growth factor β-1: affect the outcome of the radiofrequency modified maze procedure in patients with rheumatic atrial fibrillation?

[Expression and Significance of Matrix Metalloproteinase-1,9, Tissue Inhibitor of Metalloproteinase-4 and Extracellular Matrix Metalloproteinase Inducer in the Myocardium of Congestive Heart Failure in Patients with Rheumatic Heart Diseases].

Relationship of the Expression Level of Monocyte Chemotactic Protein-1 and Nuclear Factor-Κb with Atrial Fibrosis of Atrial Fibrillation Patients with Rheumatic Heart Disease